Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances.

PubWeight™: 0.91‹?›

🔗 View Article (PMID 20140815)

Published in Curr Opin Mol Ther on February 01, 2010

Authors

Geetha P Bansal1, Angela Malaspina, Jorge Flores

Author Affiliations

1: National Institute of Allergy and Infectious Diseases, Division of AIDS, National Institutes of Health, Bethesda, MD 20892, USA.

Articles citing this

Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol (2010) 1.58

Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J Virol (2013) 1.13

Viral exploitation of host SOCS protein functions. J Virol (2010) 1.01

Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa. J Acquir Immune Defic Syndr (2011) 0.97

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One (2013) 0.87

Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention. Curr HIV Res (2013) 0.87

Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther (2010) 0.84

Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials. Hum Vaccin Immunother (2013) 0.83

Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity. J Transl Med (2010) 0.80

Human immunodeficiency virus vaccines. Infect Dis Clin North Am (2014) 0.79

Species-specific differences in the expression and regulation of α4β7 integrin in various nonhuman primates. J Immunol (2015) 0.76

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost. PLoS One (2016) 0.75

Articles by these authors

Two-photon calcium imaging reveals an odor-evoked map of activity in the fly brain. Cell (2003) 6.21

Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14

The Drosophila pheromone cVA activates a sexually dimorphic neural circuit. Nature (2008) 3.65

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood (2009) 2.50

Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med (2007) 2.20

Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 2.00

Propagation of olfactory information in Drosophila. Proc Natl Acad Sci U S A (2007) 1.96

Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis (2008) 1.79

The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis (2012) 1.65

Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 1.53

Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc Natl Acad Sci U S A (2006) 1.36

Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med (2008) 1.27

Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 1.18

Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol (2011) 1.13

Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses (2005) 1.03

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis (2004) 0.97

Stripping operation with preservation of the calf saphenous veins for primary varicose veins: hemodynamic evaluation. Cardiovasc Surg (2003) 0.95

Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol (2007) 0.90

Left renal vein anomaly associated with abdominal aortic aneurysm surgery: report of a case. Surg Today (2003) 0.90

H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. Hum Vaccin Immunother (2015) 0.84

Detection of early nephropathy in Mexican patients with type 2 diabetes mellitus. Kidney Int Suppl (2005) 0.84

Continuous flow leukapheresis induces expression of stress genes in lymphocytes: impact on microarray analyses. Blood (2003) 0.82

Induction of apoptosis after stent implantation in canine portal vein. Ann Vasc Surg (2002) 0.81

Seeking new pathways for HIV vaccine discovery. Future Microbiol (2009) 0.78

Broadening inclusion of vulnerable populations in HIV vaccine trials. Expert Rev Vaccines (2008) 0.77

"In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates", NIAID Workshop Report, Bethesda, August 4, 2010. Vaccine (2011) 0.77

Model for transition from waves to synchrony in the olfactory lobe of Limax. J Comput Neurosci (2004) 0.76

Calcium imaging in the Drosophila olfactory system with a genetic indicator. Cold Spring Harb Protoc (2013) 0.75

Venous stasis ulcers due to primary, isolated deep venous insufficiency in a patient with systemic lupus erythematosus: report of a case. Surg Today (2002) 0.75

[Fibrillary glomerulo-nephritis: a rare form of glomerular disease with organized deposits]. Medicina (B Aires) (2011) 0.75

Stripping operation with sclerotherapy for primary varicose veins due to greater saphenous vein reflux: three-year results. World J Surg (2003) 0.75

[A decade of no effective inpatient medical discharges, experience from a hospital in Lima, Peru]. Rev Peru Med Exp Salud Publica (2012) 0.75